Connect Biopharma's Rademikibart Cuts COPD Exacerbations in Phase 2, Shares Jump 7.9% Premarket

Connect Biopharma Holdings (CNTB) reported positive topline results from a global Phase 2 study of rademikibart in adults with COPD and type 2 inflammation on September 30, 2026, sending shares up 7.87% to $1.05 in premarket trading after closing at $0.99. Through Week 4, the anti-IL-4Ra antibody reduced treatment failure by 81%, new moderate-to-severe exacerbations by 85%, and new emergency department visits or hospital admissions by 100% versus placebo. No new safety signals were reported. The company plans to engage with the FDA on a potential Phase 3 registrational program for rademikibart in COPD.